1387P - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
| Autor: | Hernando Cubero, J. 1, Grande, E. 2, Castellano Gauna, D. 3, Ibrahim, T. 4, Fazio, N. 5, Lopez, C. 6, Teulé, A. 7, Valle, J.W. 8, Alonso, V. 9, Molina-Cerrillo, J. 10, Tafuto, S. 11, Custodio, A. 12, Trejo, L. 1, Casteras, A. 13, Manneh Kopp, R. 3, Miqueo, C. 14, Roca Herrera, M. 1, Garcia-Carbonero, R. 3, Salazar, R. 15, Capdevila, J. 16 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v567-v567 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|